Arcutis Biotherapeutics (ARQT) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Arcutis Biotherapeutics in October 2026.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
Arcutis Biotherapeutics (ARQT) Stock Forecast
Analyst price target, next 12 months
$31.29
-1.6% vs today's $31.79
Price range over the last 12 months
Close to its 12-month high
Analysts covering Arcutis Biotherapeutics have a consensus 12-month target of $31.29, below the current price of $31.79.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 27 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arcus Biotherapeutics' stock with a target price of $31.29, indicating potential growth.
Financial Health
Arcus Biotherapeutics is showing strong revenue and cash flow, with healthy profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
